A Phase I Study of Combination Therapy with Sorafenib and 5-Fluorouracil in Patients with Advanced Hepatocellular Carcinoma.

Takuya ShoMitsuru NakanishiKenichi MorikawaMasatsugu OharaNaoki KawagishiTakaaki IzumiMachiko UmemuraJun ItoMasato NakaiGoki SudaKoji OgawaMakoto ChumaTakashi MeguroMichio NakamuraAtsushi NagasakaHiromasa HorimotoYoshiya YamamotoNaoya Sakamoto

Published in: Drugs in R&D (2018)

Combination therapy with sorafenib and 5-FU appears to be well tolerated and may have the potential to be an option for advanced HCC.

Keyphrases

combination therapy
risk assessment
climate change